Milazzo et al., 1997 [26]
|
MCF7A
|
1:4
|
[3H]Thymidine incorporation
|
Yes
|
24 hrs stim 2 hrs measure
|
Yes
|
MEM DME/F12 + 0.1 % BSA
|
Yes
|
AspB10
|
10
|
↑A,B
|
Yes
| | |
1:0.8
|
DNA measurement
|
Yes
|
3−5 days
|
Yes, every two days
|
MEM DME/F12 + 0.1 % BSA
|
Yes
|
AspB10
|
0.01−10
|
↑A,B
|
yes
| | |
MCF10B
| |
Colony forming assay
|
No
|
2 weeks
|
Yes, every two days
|
MEM DME/F12 + 2 % BSA
|
Yes
|
AspB10
|
100
|
↑A -B
|
Yes
| | |
Staiger et al., 2007 [32]
|
MCF7A
|
-
|
[3H]Thymidine incorporation
|
48hA
|
20 hrs stim 4 hrs measure
|
Yes
|
DME/F12 SFM
|
No
|
Glargine
|
10, 50, 100
|
↓A
|
No
| | |
MCF10B
|
-
|
MTT
|
24hB
|
4 days
|
Yes, every two days
|
DME/F12 SFM
|
No
|
Glargine
|
1, 5, 10, 25
|
↑A,B
|
No
| | |
No
|
Liefvendahl et al., 2008 [24]
|
MCF7 SKBR-3
|
1:20
|
[3H]Thymidine incorporation
|
24 hrs
|
21 hrs stim 3 hrs measure
|
No
|
DMEM SFM
|
No
|
Glargine
|
0.01−100
|
-
| | | |
1:1.8
|
Mayer et al., 2008 [25]
|
MCF7A
|
1:3
|
Cristal violet cell staining
|
No
|
4 days
|
No
|
DMEM + 1 % SD-FBS
|
No
|
Aspart
|
1.5A,B
| | | | |
Lispro
|
15A,B
| | |
MCF10AB
|
1:1.2
|
Glargine
|
1500C
|
↑A
|
YesA
|
Glulisine
|
T47DC
|
1:2
|
Detemir
|
Shukla et al., 2009 [31]
|
MCF7A
|
-
|
Cristal violet cell staining
|
24 hrs
|
3 daysA
|
Yes, every 24 hrs
|
DMEM + 2 % CDFBS
|
No
|
Aspart
|
1.5, 15, 150,
|
↑A
|
No
| | |
Lispro
|
1500
|
-
| |
2 daysB
|
MEGMB
|
Glargine
|
↑A
|
yes
|
Detemir
|
↓A
|
No
|
MCF10AB
|
-
|
WB
|
24 hrs
|
10 min
|
-
|
DMEM + 2 % CDFBS
|
No
|
Aspart
| | | |
-
|
-
|
Lispro
| | | |
-
|
-
|
MEGMB
|
Glargine
| | |
Yes
|
↑A,B
|
↑A
|
Detemir
| | |
Yes
|
↓A
|
-
|
Shukla et al., 2009 [30]
|
MCF7A
|
-
|
Cristal violet cell staining
|
24 hrs
|
3 daysA
|
Yes, every 24 hrs
|
DMEM + 2 % CDFBS
|
No
|
Glulisine
|
1.5, 15, 150, 1500
|
↓AB
|
No
| | |
MCF10AB
|
-
|
2 daysB
|
MEGM
|
MMOC/ki67 nuclei count
|
No
|
3 days
|
No
|
Waymouth medium SFM
| |
Glulisine
|
750
|
↓
|
No
| | |
WB
|
24 hrs
|
10 min
|
-
|
DMEM + 2 % CDFBSA
|
No
|
Glulisine
| | |
Yes
|
↓AB
|
↓AB
|
MEGMB
|
Weinstein et al., 2010 [35]
|
MCF7
|
-
|
Cell counting
|
No
|
72 hrs
|
Yes every day
|
DMEM/SFM
| |
Glargine
|
100
|
↑
|
No
| | |
Detemir
|
↑
|
No
|
Oleksiewicz et al., 2011 [27]
|
MCF7
|
-
|
FACS
|
72 hrs
|
24−30 hrs
|
No
|
DMEM + 0.1 % FCS
|
No
|
X10
|
0.074−2
|
↑
|
Yes
| | |
WB
|
72 hrs
|
20−40 min
|
No
|
DMEM + 0.1 % FCS
|
No
|
X10
|
0.67, 2
| |
Yes
|
↑
|
↑
|
Teng et al., 2011 [33]
|
MCF7A
|
-
|
MTT
|
24 hours
|
2 days
|
Yes, every two days
|
RPMI + 0.5 % CS-FBS
|
No
|
Glargine
|
20−200
|
↑A
|
Yes
| | |
Yes
|
WB
|
No
|
0, 30, 60, 120, 240 min
|
No
|
RPMI + 0.5 % CS-FBS
|
No
|
Glargine
|
100nM
|
↑A
| | | |
FACS anti-apoptotic
|
No
|
48 hrs
|
No
|
RPMI + 0.5 % CS-FBS
| |
Glargine
| |
↑A anti-Apoptotic response
|
Yes
| | |
Glendorf et al., 2012 [21]
|
HMEC
|
1:20
|
[3H]Thymidine incorporation
|
No
|
70 hrs stim 2 hrs measure
|
No
|
MEGM
|
?
|
B10A,
|
0.0001−1000
|
↓
| | | |
B10R,
|
↓
|
X10,
|
↑
|
B10Q,
|
↑
|
B10E,
|
↑
|
B10H,
|
↓
|
B10I,
|
↓
|
B10F,
|
↓
|
B10W,
|
↓
|
B10V
|
↓
|
Hansen et al., 2012 [22]
|
HMECA
|
1:21
|
[3H]Thymidine incorporation
|
24 hrs
|
70 hrs stim 2 hrs measure
|
No
|
MEGM
|
No
|
Detemir
|
0.001−1000
|
↓A
|
Yes
| | |
Glargine
|
↑A
|
Yes
|
X10
|
↑A
|
Yes
|
Knudsen et al., 2012 [23]
|
MCF7A
|
-
|
[3H]Thymidine incorporation
|
2 hrs
|
24 hrs stim 2 hrs measure
|
No
|
DMEM + 0.1 % serum
|
No
|
S961
|
0.0001−100
|
↑A
| | | |
Pierre-Eugene et al., 2012 [28]
|
MCF7A
|
-
|
BRET-PIP3
|
No
|
45 min
|
No
|
DMEM/F12 + 5 % FBS
|
?
|
Aspart
| | | |
-
| |
MDA-MB-231B
|
-
| | | | | | |
Lispro
| | | |
-
|
Glargine
| | |
Yes
|
↑A
|
M1
| | | |
↓A
|
M2
| | | |
↓A
|
Glulisine
| | |
Yes
|
↓A
|
Detemir
| | |
Yes
|
↓B
|
WB
|
12
|
5 or 20 min
|
No
|
DMEM/F12
|
?
|
Glargine
| | | |
↑A
|
↑A
|
SFM
| |
M1
| | | |
-
|
-
|
M2
| | | |
-
|
-
|
[14C]Thymidine incorporation
|
4 hrs
|
19 hrs stim 6 hrs measure
|
No
|
DMEM/F12 SFM
|
?
|
Glargine
|
0.01−1000
|
↑A
| | | |
M1
| |
-
|
M2
| |
-
|
Gallagher et al., 2013 [20]
|
MET1
| |
WB
|
1 hr
|
10 min
|
No
|
DMEM + 0.1 % BSA
| |
X10
|
10
|
↑
|
Yes
| | |
MVT1
|
Ter Braak et al., 2014 [34]
|
MCF7 IGF1RA
|
1:25
|
WB
| |
30 min
|
No
|
RPMI + 5 % CDFBS
|
No
|
Aspart
|
10, 33, 100
| | |
-
|
-
|
MCF7 INSRB
|
1:0.02
|
Lispro
| | |
Yes
|
↑A
|
-
|
MCF7 INSRC
|
1:0.07
|
Glargine
| | |
↑A
|
↑ABC
| |
M1
| | | |
-
|
-
|
M2
| | | |
-
|
-
|
Glulisine
| | |
-
|
-
| |
Detemir
| | |
Yes
|
↓AB C
|
↓ABC
|
X10
| | |
Yes
|
↑A
|
↑ABC
|
SRB
|
24 hrs
|
4 days
|
Yes
|
RPMI + 5 % CDFBS
|
No
|
Aspart
|
0.01−100
|
-
| | | |
Lispro
| |
-
| |
Glargine
| |
↑
|
Yes
|
M1
| |
-
| |
M2
| |
-
| |
Glulisine
| |
-
| |
Detemir
| |
↓
|
Yes
|
X10
| |
↑
|
Yes
|
Sciacca et al., 2014 [29]
|
MCF7A
|
1:6
|
BRDU incorporation
|
24 hrs
|
12 hrs, 6 hrs measure
|
No
|
MEM SFM
|
?
|
Aspart
|
5 nM
|
↓A –B,C,D
| | | |
MDA-MB-
|
1:2
|
Lispro
|
(only detemir
|
-A,C,D ↑B
|
YesB
|
157B
| |
Glargine
|
at 19 nM)
|
-A,C,D ↑B
|
YesB
|
MDA-MB-468C
|
1:0.2
|
M1
| |
-A,B,D ↓C
| |
T47DD
|
1:8
|
M2
| |
↑A -B,D ↓C
| |
Glulisine
| |
-A,C,D ↑B
|
YesB
|
Detemir
| |
-A,C,D ↑B
|
YesB
|
X10
| |
↑A,B –c,D
|
YesB
|
Collagen invasion assay (Boyden chamber technique)
|
No
|
18 hrs
|
No
|
MEM SFM
|
?
|
Aspart
| |
-A,D, ↑B,C
| | | |
Lispro
| |
-A,D ↑B,C
|
Glargine
| |
↑A,B,C ↓D
|
M1
| |
↑A,C –B,D
|
M2
| |
-A,D ↑B,C
|
Glulisine
| |
↓A,D ↑B,C
|
Detemir
| |
↑A,B,C,D
|
X10
| |
↑A,B,C,D
|